Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer
Clinical trial NCT05402722 · UNKNOWN
Trial details
- NCT number
- NCT05402722
- Sponsor
- Beijing 302 Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-01
- Primary completion
- 2022-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.